IMGN-779 shows a compelling therapeutic option within acute leukemia arena. This novel unmodified antibody specifically recognizes CD33, the marker present by nearly all immature myeloid cells. Compared to conventional ADCs, IMGN-779 triggers an immune system activation excluding the conjugate drug,